BioGaia AB (BIOG.B) AI Stock Analysis

• Market Cap: kr10.31B
• Dividend Yield: 1.92%
• Average Volume (3M): 124.05K
• Price to Earnings (P/E): 32.3
• Beta (1Y): 0.39
• Revenue Growth: 7.88%
• EPS Growth: -6.35%
• Country: SE
• Employees: 224
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.87
• Shares Outstanding: 98,497,170
• 10 Day Avg. Volume: 90,103
• 30 Day Avg. Volume: 124,054
• PEG Ratio: -7.77
• Price to Book (P/B): 6.56
• Price to Sales (P/S): 7.95
• P/FCF Ratio: 31.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: kr116.00 ▲(14.74% Upside)

BioGaia AB's strong financial performance is the most significant factor, showcasing robust profitability and a solid equity structure. Technical analysis indicates potential short-term weakness, while valuation metrics suggest the stock may be overvalued. The absence of earnings call data and corporate events limits additional insights.

BioGaia AB Business Overview & Revenue Model

Company Description

BioGaia AB is a Swedish biotechnology company specializing in the development and commercialization of probiotic products. Founded in 1990, the company focuses on the health benefits of probiotics, primarily targeting gastrointestinal health, oral health, and immune support. BioGaia's core products include probiotic dietary supplements, food products, and medical devices that contain its patented strains of Lactobacillus reuteri. The company operates in various sectors, including consumer health, pharmaceuticals, and medical nutrition, and collaborates with partners across the globe to enhance the reach and efficacy of its offerings.

How the Company Makes Money

BioGaia generates revenue primarily through the sale of its probiotic products, which include dietary supplements, functional foods, and medical devices. The company operates a business model that leverages both direct sales and partnerships with established distributors and retailers. Key revenue streams include sales to pharmacies, health food stores, and online platforms, as well as collaborations with healthcare professionals and institutions. Additionally, BioGaia engages in licensing agreements with third parties to utilize its proprietary strains of probiotics, which further diversifies its income. Strategic partnerships with global healthcare companies also play a significant role in expanding its product distribution and enhancing brand visibility, contributing positively to its overall earnings.

BioGaia AB Financial Statement Overview

Summary

BioGaia AB is in a strong financial position with robust profitability, excellent equity structure, and healthy cash flow management. While the company exhibits revenue growth and strong profit margins, minor operational efficiency challenges and cash flow variability should be monitored.

Income Statement

BioGaia AB has demonstrated strong financial performance with consistent revenue growth and healthy profit margins. The gross profit margin remained robust at 72.46% for 2024, reflecting efficient cost management. Net profit margin was similarly strong at 24.70%, indicating effective control over operating expenses. Revenue growth rate from 2023 to 2024 was 9.76%, showcasing positive upward trajectory. However, a slight decline in EBIT margin from 34.18% to 29.76% suggests potential challenges in operational efficiency.

Balance Sheet

The balance sheet of BioGaia AB is solid with a remarkable equity ratio of 84.77% for 2024, indicating financial stability and low reliance on debt. The debt-to-equity ratio is effectively zero, showcasing a strong capital structure with no debt burden. However, slight declines in stockholders' equity over the years may warrant attention.

Cash Flow

BioGaia AB has shown stable cash flow management with a free cash flow of SEK 359.07 million for 2024. The operating cash flow to net income ratio of 1.06 reflects good cash generation relative to earnings. However, a decrease in free cash flow growth rate from previous years suggests potential operational cash constraints.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.44B	1.42B	1.30B	1.10B	785.11M	747.08M
Gross Profit	1.04B	1.03B	950.19M	801.93M	582.95M	546.92M
EBITDA	457.51M	539.44M	494.92M	476.89M	276.86M	248.84M
Net Income	286.63M	351.39M	365.35M	373.77M	196.27M	179.73M
Balance Sheet
Total Assets	1.43B	2.03B	2.33B	2.21B	2.13B	1.91B
Cash, Cash Equivalents and Short-Term Investments	622.34M	1.22B	1.54B	1.49B	1.48B	1.47B
Total Debt	0.00	7.10M	8.80M	20.09M	10.40M	8.90M
Total Liabilities	277.75M	310.07M	302.85M	241.55M	250.69M	167.04M
Stockholders Equity	1.15B	1.72B	2.03B	1.97B	1.88B	1.75B
Cash Flow
Free Cash Flow	310.06M	359.06M	377.25M	301.03M	215.50M	205.18M
Operating Cash Flow	316.16M	373.22M	425.96M	318.94M	221.88M	221.26M
Investing Cash Flow	-6.02M	-14.07M	-50.94M	-18.14M	-126.97M	-16.07M
Financing Cash Flow	-689.88M	-689.72M	-308.42M	-313.59M	-81.85M	1.05B

BioGaia AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 101.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOG.B, the sentiment is Negative. The current price of 101.1 is below the 20-day moving average (MA) of 101.16, below the 50-day MA of 104.50, and below the 200-day MA of 103.65, indicating a bearish trend. The MACD of -0.69 indicates Negative momentum. The RSI at 44.86 is Neutral, neither overbought nor oversold. The STOCH value of 37.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOG.B.

BioGaia AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOG.B	73 Outperform	kr10.31B	32.31	22.26%	1.92%	7.88%	-6.35%
SECARE	63 Neutral	€5.75B	90.91	0.88%	0.67%	6.65%	1.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORX	47 Neutral	kr919.10M	―	―	―	-8.79%	-91.09%
ALZCUR	47 Neutral	kr222.93M	―	-90.66%	―	―	15.74%
NANEXA	39 Underperform	€277.41M	-8.29	-48.65%	―	-60.33%	58.04%
ENZY	38 Underperform	kr446.63M	―	―	―	19.17%	24.53%

BioGaia AB Corporate Events

BioGaia AB Reports Q3 2025 Growth and Strategic Initiatives

BioGaia AB reported a 7% increase in net sales for the third quarter of 2025, driven by growth in both its Pediatrics and Adult Health segments. The company launched BioGaia New Sciences AB to focus on microbiome research, established its own distribution in Germany and Austria, and introduced a new product, Prodentis® Fresh Breath. Despite a decrease in adjusted operating profit and profit after tax, the company saw a significant rise in operating profit and earnings per share, indicating strong operational performance. Key leadership changes and strategic initiatives, including a new chairman and a study publication, highlight BioGaia’s commitment to strengthening its market position and expanding its research capabilities.

The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK115.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.

BioGaia Unveils New Probiotic Strain with Enhanced Benefits

BioGaia AB has announced the publication of its new patented strain, L. reuteri BG-R46®, in the journal Beneficial Microbes. Developed in collaboration with the Swedish University of Agricultural Sciences, this strain exhibits enhanced bile tolerance and adenosine production, supporting gut health and anti-inflammatory properties. This advancement underscores BioGaia’s commitment to pioneering microbiome science and maintaining its leadership in the probiotic industry.

The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK115.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.

BioGaia to Release Q3 2025 Financial Report and Host Live Audiocast

BioGaia is set to release its financial report for the third quarter of 2025 on October 22, 2025. Following the release, CEO Theresa Agnew and CFO Alexander Kotsinas will discuss the report and answer questions in a live audiocast, which indicates the company’s commitment to transparency and stakeholder engagement.

The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK115.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.

BioGaia Introduces Probiotic Solution for Fresh Breath and Oral Health

BioGaia has launched Prodentis® FRESH BREATH, a probiotic lozenge designed to promote fresh breath and support oral health by combining zinc and patented probiotics. This product enhances BioGaia’s oral care portfolio and positions the company at the forefront of science-backed solutions for oral health, addressing the global demand for natural and effective oral care products.

The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK115.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.

BioGaia Expands Direct Distribution to Germany and Austria

BioGaia AB is expanding its direct market presence by establishing its own distribution in Germany and Austria through a new subsidiary named BiGaia. This strategic move, effective from early 2026, aims to strengthen BioGaia’s position in the growing probiotic supplements market in these regions, which is expected to see significant growth by 2030. The company has appointed Jean Bouvain as Managing Director for BiGaia Germany and Austria, leveraging his extensive experience in the OTC self-medication and health supplement sectors to drive the business forward. This decision marks a shift from BioGaia’s previous collaboration with a local distribution partner for pediatric products, allowing the company to directly market both its pediatric and adult probiotic products.

The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK115.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.

BioGaia’s Probiotic Proven to Prevent Antibiotic-Associated Diarrhea in Children

BioGaia AB has announced the results of a study published in the European Journal of Pediatrics, demonstrating that their patented probiotic strain, Limosilactobacillus reuteri DSM 17938, effectively prevents antibiotic-associated diarrhea (AAD) in children. The PEARL Study, a large-scale, multi-center, randomized, placebo-controlled clinical trial, showed significant reductions in AAD incidence among children treated with the probiotic, particularly those with acute otitis media. This finding strengthens BioGaia’s position as a leader in probiotics, highlighting the potential of L. reuteri DSM 17938 as a safe adjunct to antibiotic therapy in pediatric care, thus supporting their mission to promote health through the microbiome.

The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK115.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.

BioGaia Chairman Mauricio Graber Invests in Company Shares

Mauricio Graber, the newly elected chairman of BioGaia’s board, has purchased 735,754 class B shares from Anatom Holding, the company’s anchor shareholder. This significant investment demonstrates Graber’s commitment to supporting BioGaia’s future development and aligns his interests with those of other stakeholders, potentially strengthening the company’s strategic direction and market position.